As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...